Abstract
A two-dose regimen of the Oxford-AstraZeneca (ChAdOx1) Covid-19 vaccine with an inter-dose interval of three months has been implemented in many countries with restricted vaccine supply. However, there is limited evidence for the effectiveness of ChAdOx1 by dose in elderly populations in countries with high prevalence of the Gamma variant of SARS-CoV-2. Here, we estimate ChAdOx1 effectiveness by dose against the primary endpoint of RT-PCR-confirmed Covid-19, and secondary endpoints of Covid-19 hospitalization and Covid-19-related death, in adults aged ≥60 years during an epidemic with high Gamma variant prevalence in São Paulo state, Brazil using a matched, test-negative case-control study. Starting 28 days after the first dose, effectiveness of a single dose of ChAdOx1 is 33.4% (95% CI, 26.4–39.7) against Covid-19, 55.1% (95% CI, 46.6–62.2) against hospitalization, and 61.8% (95% CI, 48.9–71.4) against death. Starting 14 days after the second dose, effectiveness of the two-dose schedule is 77.9% (95% CI, 69.2–84.2) against Covid-19, 87.6% (95% CI, 78.2–92.9) against hospitalization, and 93.6% (95% CI, 81.9–97.7) against death. Completion of the ChAdOx1 vaccine schedule affords significantly increased protection over a single dose against mild and severe Covid-19 outcomes in elderly individuals during widespread Gamma variant circulation.
Highlights
A two-dose regimen of the Oxford-AstraZeneca (ChAdOx1) Covid-19 vaccine with an interdose interval of three months has been implemented in many countries with restricted vaccine supply
We evaluate vaccine effectiveness following one and two doses during a epidemic with high Gamma variant prevalence in São Paulo, the most populous state in Brazil
We show that the effectiveness of the completed two-dose schedule is higher than effectiveness of a single dose, and demonstrate robust ChAdOx1 vaccine effectiveness against moderate and severe Covid-19 outcomes in this elderly population
Summary
A two-dose regimen of the Oxford-AstraZeneca (ChAdOx1) Covid-19 vaccine with an interdose interval of three months has been implemented in many countries with restricted vaccine supply. There is limited evidence for the effectiveness of ChAdOx1 by dose in elderly populations in countries with high prevalence of the Gamma variant of SARS-CoV-2. Multiple vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the etiologic agent that causes coronavirus disease 19 (Covid-19), have been developed, proven efficacious, and deployed in mass vaccination campaigns[1,2,3]. Prominent among these vaccines, in lower-income and middle-income countries, is the viral vector vaccine, ChAdOx14. We show that the effectiveness of the completed two-dose schedule is higher than effectiveness of a single dose, and demonstrate robust ChAdOx1 vaccine effectiveness against moderate and severe Covid-19 outcomes in this elderly population
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
